7 Hills Pharma

Executive Summary

7 Hills Pharma is a clinical-stage biotechnology company pioneering first-in-class small molecule integrin agonists to augment immunotherapy for cancer and improve cell and gene therapies. Founded in 2015 and headquartered in Cincinnati, Ohio, the company's lead programs focus on overcoming resistance to immune checkpoint inhibitors in solid tumors and enhancing hematopoietic stem cell transplantation. By targeting integrin-mediated adhesion and signaling, 7 Hills aims to boost the efficacy of existing immunotherapies and enable more effective cell therapies. The company is privately held and has not disclosed its funding history or valuation, but its innovative approach addresses significant unmet needs in oncology and regenerative medicine. With a strong scientific foundation and a clear therapeutic rationale, 7 Hills Pharma is positioned to advance its pipeline through preclinical and early clinical development. However, as a private, early-stage company, it faces typical risks associated with clinical trials and regulatory pathways.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 trial for lead integrin agonist in solid tumors40% success
• TBDPreclinical proof-of-concept data for integrin agonist in cell therapy enhancement50% success
• TBDPotential partnership or licensing deal for integrin agonist platform30% success